7 September 2010
Saffron Walden, UK and New York, US: BioFocus and the Usher III Initiative, Inc., a not-for-profit organization, announced today that they have embarked on a drug discovery project focused on Usher Syndrome Type III. Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.

“We are pleased to support the Usher III Initiative in its aim to find a targeted treatment and cure for Usher III,” said Angus MacLeod, Vice President, Medicinal Chemistry, BioFocus. “This collaboration will utilize BioFocus’ expertise in integrated drug discovery programs.”

www.biofocus.com